scholarly journals Comparison of Efficiencies of Michigan Neuropathy Screening Instrument, Neurothesiometer, and Electromyography for Diagnosis of Diabetic Neuropathy

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Turkan Mete ◽  
Yusuf Aydin ◽  
Mustafa Saka ◽  
Halise Cinar Yavuz ◽  
Sule Bilen ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Physical Examination ◽  
Diabetic Peripheral Neuropathy ◽  
Diabetes Type 2 ◽  
Screening Instrument ◽  
Diabetes Type ◽  
Diabetic Patients ◽  
Patients With Diabetes ◽  
Michigan Neuropathy Screening Instrument

Aim. This study compares the effectiveness of Michigan Neuropathy Screening Instrument (MNSI), neurothesiometer, and electromyography (EMG) in detecting diabetic peripheral neuropathy in patients with diabetes type 2.Materials and Methods. 106 patients with diabetes type 2 treated at the outpatient clinic of Ankara Numune Education and Research Hospital Department of Endocrinology between September 2008 and May 2009 were included in this study. Patients were evaluated by glycemic regulation tests, MNSI (questionnaire and physical examination), EMG (for detecting sensorial and motor defects in right median, ulnar, posterior tibial, and bilateral sural nerves), and neurothesiometer (for detecting alterations in cold and warm sensations as well as vibratory sensations).Results. According to the MNSI score, there was diabetic peripheral neuropathy in 34 (32.1%) patients (score ≥2.5). However, when the patients were evaluated by EMG and neurothesiometer, neurological impairments were detected in 49 (46.2%) and 79 (74.5%) patients, respectively.Conclusion. According to our findings, questionnaires and physical examination often present lower diabetic peripheral neuropathy prevalence. Hence, we recommend that in the evaluation of diabetic patients neurological tests should be used for more accurate results and thus early treatment options to prevent neuropathic complications.

scholarly journals CORRELATION BETWEEN FATTY BINDING PROTEIN 1 (FABP1) AND DIABETES TYPE 2 (T2DM)

2021 ◽  
Vol 9 (06) ◽  
pp. 645-650
Author(s):  
Sofia Ashraf Abd Elhady ◽  
◽  
Asmaa Mohamed Mansour ◽  
Hassan Shalby ◽  
Naglaa Fawazy ◽  
...  
Keyword(s):  
Binding Protein ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Control Group ◽  
Diabetic Patients ◽  
Fasting Insulin ◽  
Fatty Acid Binding ◽  
Patients With Diabetes ◽  
Novel Biomarkers

Background: Diabetes mellitus is best described as a condition that is characterized by postprandial hyperglycemia that has two types; diabetes type 1 and type 2. Many patients with type 2 diabetes can be asymptomatic. There are many novel biomarkers for the detection of diabetes type 2, such as FABP1, which is investigated as a marker to detect patients with diabetes type 2. Aim: The aim of the study was to investigate FABP1 in Patients with diabetes type 2 and to find the correlations between FABP1 and fasting insulin in those patients. Methods: Samples were collected from 99 diabetic patients and 85 samples of healthy participants as the control group. All participants were subjected to liver enzymes (ALT and AST) lipid profile (triglycerides, HDL, LDL, and cholesterol), T-billirbun, Albumin, Alp, AFP, BMI, S-creatinine, Hb, Fatty acids, F. Insulin, CA19.9, HbA1c, and Fbs that were done by an autoanalyzer. The serum level of fatty acid-binding protein 1 was measured by SunRed human FABP1 Elisa kits. Results: Data was represented as mean ± standard deviation or median with statistically significant values of ALT, AST, ALP, PT, and INR (at P< 0.05). Findings revealed a significant positive correlation between our marker FABP1 and TG, cholesterol, LDL, Fasting insulin, and CA19.9, Conclusion: FABP1 can be used as a novel marker to detect patients with diabetes type 2.

Risk Factors Associated With Hyperuricemia in Patients with Diabetes Type 2: About 190 Cases

2020 ◽  
Vol 2 (1) ◽  
pp. 12-16
Author(s):  
Fennoun H ◽  
Haraj NE ◽  
El Aziz S ◽  
Bensbaa S ◽  
Chadli A
Keyword(s):  
Type 2 Diabetes ◽  
Heart Disease ◽  
Glycemic Control ◽  
Ischemic Heart Disease ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Ischemic Heart ◽  
Factors Associated ◽  
Patients With Diabetes

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

scholarly journals Albumin-Creatinine Ratio is More Diagnostic Sensitive than Cystatin-C in Assessment of Diabetic Peripheral Neuropathy

2018 ◽  
Vol 1 (3) ◽  
Keyword(s):  
Diabetes Mellitus ◽  
Peripheral Neuropathy ◽  
Cystatin C ◽  
Early Treatment ◽  
Diabetic Peripheral Neuropathy ◽  
Diabetic Patients ◽  
Creatinine Ratio ◽  
Serum Cystatin C ◽  
Albumin Creatinine Ratio

Background: Diabetic Peripheral neuropathy is one of the most common cardiovascular complications among diabetes mellitus patients and occurs in more than half of the population of diabetic patients world-wide. It is a common cause of foot ulcer, gangrene and amputation among diabetics. Thus, its prevention or early treatment can improve the quality of life of diabetic patients. In a bid to reduce it, various biochemical markers have been evaluated to enable early treatment and amelioration of diabetic neuropathy among diabetes mellitus patients. Aim: Evaluation of the diagnostic relevance of Cystatin-C versus Albumin-creatinine ratio in assessment of Peripheral neuropathy in diabetic type 2 subjects. Method: 102 type 2 DM subjects (66 females and 36 males) and 100 control subjects of same age range (40 – 80 years) were recruited for this study which includes 51 subjects with peripheral neuropathy and 51 subjects without peripheral neuropathy. Serum Cystatin-C, Microalbuminuria, Urine creatinine and HBA1c were analysed with standard methods. Results: Cystatin-C, Microalbuminuria, Albumin-creatinine ratio and Glycated haemoglobin were significantly elevated (P<0.05) in diabetic subjects compared to the control. Cystatin-C (ng/ml), microalbuminuria (mg/l), albumin creatinine ratio (mg/mmol) and HBA1c (%) is [105.52 ± 45.11; 90.07±20.29; 10.48 ± 4.82; 6.9±1.7] respectively. Microalbuminuria, albumin creatinine ratio showed significant increase (P<0.05) in subjects with peripheral neuropathy compared to those subjects without [92.11± 22.82; 35.70±16.35; 2.61±1.1; 6.38±1.79]. The ROC curve shows that Albumin-creatinine ratio showed significant (P<0.05) sensitivity to peripheral neuropathy [AUC=0.714] while Cystatin-C showed no significant (P<0.05) sensitivity to peripheral neuropathy complication [AUC=0.553]. Conclusion: Cystatin-C was found to be deranged in diabetics. However, Albumin-creatinine ratio showed more diagnostic sensitivity for peripheral neuropathy than Cystatin-C.

scholarly journals The Effects of Combined Insulin and Metformin Therapy in Obese Patients with Diabetes Mellits Type 2 in the Early Stage of the Disease

2006 ◽  
Vol 6 (2) ◽  
pp. 54-58
Author(s):  
Belma Aščić - Buturović
Keyword(s):  
Insulin Therapy ◽  
Pancreatic Beta Cells ◽  
Early Stage ◽  
Diabetes Type 2 ◽  
Diabetes Type ◽  
Target Cells ◽  
Obese Patients ◽  
Patients With Diabetes ◽  
Insulin Activity

Combination of insulin and metformin has been shown to improve glycaemic control in clinical trials, particularly in obese patients with diabetes type 2. Insulin therapy can improve function of pancreatic beta cells and periphery insulin activity in target cells in order to enhance glycaemic homeostasis (1, 2, 3). In our study we included obese patients with diabetes type 2 in the early stage of the disease. The study is partially retrospective and partially prospective. The study encompassed 40 patients split in two groups. The first group of 20 patients received insulin therapy combined with metformin, while the patients of the second group were treated with oral antidiabetic drugs, sulfonylureas and metformin. Three months later, the group treated with insulin and metformin showed improvement in the monitored parameters, namely significant reduction in HbA1c (p = 0.003), MFBG (p = 0.0009), PPG (p = 0.028). Insulin therapy administered together with metformin, in obese patients with diabetes type 2, in the early stage of the disease, resulted in well regulated fasting blood glycaemia, as well as post challenge glycaemia and HbA1c.

Sign in / Sign up

Export Citation Format

Share Document